Peplin Inc. Initiates its Final Phase 3 Clinical Trial for PEP005 Gel in AK

Published: Jul 24, 2009

EMERYVILLE, Calif. & BRISBANE, Queensland--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced the initiation of its second non-head Phase 3 clinical trial to confirm the efficacy and safety of PEP005 (ingenol mebutate) gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to non-head locations, which include the trunk and extremities.

Back to news